-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Receives Average Rating of "Moderate Buy" From Brokerages
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Receives Average Rating of "Moderate Buy" From Brokerages
Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.81.
A number of equities analysts recently issued reports on DNA shares. BTIG Research boosted their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. Jefferies Financial Group dropped their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Finally, Raymond James boosted their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th.
Get Ginkgo Bioworks alerts:Ginkgo Bioworks Trading Down 4.2 %
DNA opened at $2.94 on Wednesday. The business has a fifty day moving average of $2.97 and a 200 day moving average of $3.06. Ginkgo Bioworks has a 52-week low of $2.09 and a 52-week high of $15.86. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84.
Institutional Investors Weigh In On Ginkgo Bioworks
A number of institutional investors and hedge funds have recently bought and sold shares of the company. FDx Advisors Inc. bought a new position in shares of Ginkgo Bioworks in the 1st quarter worth $150,000. Exos Asset Management LLC raised its position in shares of Ginkgo Bioworks by 68.1% in the 1st quarter. Exos Asset Management LLC now owns 22,861 shares of the company's stock worth $92,000 after acquiring an additional 9,261 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Ginkgo Bioworks by 315.2% in the 4th quarter. Cubist Systematic Strategies LLC now owns 1,156,832 shares of the company's stock worth $9,613,000 after acquiring an additional 878,232 shares in the last quarter. FNY Investment Advisers LLC raised its position in shares of Ginkgo Bioworks by 17.6% in the 2nd quarter. FNY Investment Advisers LLC now owns 102,680 shares of the company's stock worth $244,000 after acquiring an additional 15,375 shares in the last quarter. Finally, Wealthstream Advisors Inc. bought a new position in shares of Ginkgo Bioworks in the 1st quarter worth $378,000. 53.37% of the stock is owned by institutional investors.About Ginkgo Bioworks
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Further Reading
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.81.
據MarketBeat.com報道，Ginkgo Bioworks Holdings，Inc.(紐約證券交易所代碼：DNA-GET Rating)的股票已被覆蓋該股票的七家評級公司一致給予“適度買入”的建議。一位股票研究分析師對該股的評級為賣出，一位分析師給出了持有評級，四位分析師給出了該公司的買入評級。在過去一年發佈該股報告的分析師中，1年目標價的平均水平為7.81美元。
A number of equities analysts recently issued reports on DNA shares. BTIG Research boosted their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday, August 16th. Jefferies Financial Group dropped their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a report on Thursday, June 16th. Finally, Raymond James boosted their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the company an "outperform" rating in a report on Tuesday, August 16th.
一些股票分析師最近發佈了關於DNA股票的報告。BTIG Research在8月16日週二的一份報告中將他們對銀杏生物工場的目標價從5.00美元上調至6.00美元，並給予該公司“買入”評級。在6月16日星期四的一份報告中，傑富瑞金融集團將銀杏生物工程的目標價格從11.50美元下調至4.35美元。最後，雷蒙德·詹姆斯在8月16日星期二的一份報告中將銀杏生物科技公司的目標價從11.50美元上調至14.50美元，並給予該公司“跑贏大盤”的評級。
Ginkgo Bioworks Trading Down 4.2 %
銀杏生物工場股價下跌4.2%
DNA opened at $2.94 on Wednesday. The business has a fifty day moving average of $2.97 and a 200 day moving average of $3.06. Ginkgo Bioworks has a 52-week low of $2.09 and a 52-week high of $15.86. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84.
DNA週三開盤報2.94美元。該業務的50日移動均線切入位在2.97美元，200日移動均線切入位在3.06美元。銀杏生物工場的52周低點為2.09美元，52周高位為15.86美元。該公司的負債權益比率為0.03，速動比率為11.78，流動比率為11.84。
Institutional Investors Weigh In On Ginkgo Bioworks
機構投資者參與銀杏生物工程
About Ginkgo Bioworks
關於銀杏生物工場
(Get Rating)
(獲取評級)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
銀杏生物工程控股公司及其子公司開發細胞編程平臺。它的平臺用於對細胞進行編程，以實現產品的生物生產，如新型療法、食品配料和從石油中提取的化學品。該公司服務於各種終端市場，包括特種化學品、農業、食品、消費品和藥品。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
- 免費獲取StockNews.com關於銀杏生物工程(DNA)的研究報告
- 3家航空公司股票陷入持有格局
- Roku股票下跌，但並未出局
- 如果你渴望價值，那就嚐嚐露絲的好客之道吧
- 福特在第三季度發出警告後是否正在反彈
- AMD股票是不是跌得太厲害了？
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《銀杏生物工場日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對銀杏生物工程和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧